White Papers and Resources
Please find below the latest White Papers provided by agencies and companies within the healthcare and pharmaceutical industry. These are provided by external comoanies and are not approved of, checked or edited by PMLiVE or PMGroup Worldwide Ltd.
Archetypes: Rethinking go-to-market expectations to drive commercial success
June 6, 2023 | White Papers and Resources |
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach …
Brought to you by Avalere Health
Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
May 31, 2023 | White Papers and Resources |
Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this …
Brought to you by Avalere Health
The challenges of reimbursement and innovative pricing for cell and gene therapies
March 16, 2023 | White Papers and Resources |
Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss …
Brought to you by Avalere Health
Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes
March 16, 2023 | White Papers and Resources |
Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant …
Brought to you by Avalere Health
5 ways we’re enhancing our services to support our clients in 2023
January 31, 2023 | White Papers and Resources |
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.
Brought to you by Avalere Health
Why it’s time to apply a payer lens to your early pipeline planning
November 9, 2022 | White Papers and Resources |
Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets …
Brought to you by Avalere Health
The fast-paced future of cell and gene therapies
November 3, 2022 | White Papers and Resources |
In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share …
Brought to you by Avalere Health
Omnichannel scientific engagement and the use of archetypes to drive personalization
October 27, 2022 | White Papers and Resources |
Natasha Cowan, Senior Corporate Communications Manager, explores with Gary Lyons, Head of Strategy, his recent plenary session at the 18th Annual ISMPP conference that focused …
Brought to you by Avalere Health
The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia
October 12, 2022 | White Papers and Resources |
With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a …
Brought to you by Avalere Health
Report: Reinventing product and portfolio value for the biopharmaceutical industry
October 4, 2022 | White Papers and Resources |
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements …
Brought to you by Avalere Health